| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2003PNAS..10013555L |
| P356 | DOI | 10.1073/PNAS.2234683100 |
| P953 | full work available at URL | https://europepmc.org/articles/pmc263852?pdf=render |
| https://doi.org/10.1073/pnas.2234683100 | ||
| https://europepmc.org/articles/PMC263852 | ||
| https://europepmc.org/articles/PMC263852?pdf=render | ||
| https://pnas.org/doi/pdf/10.1073/pnas.2234683100 | ||
| P932 | PMC publication ID | 263852 |
| P698 | PubMed publication ID | 14573704 |
| P5875 | ResearchGate publication ID | 9041976 |
| P50 | author | Feng Li | Q93194296 |
| P2093 | author name string | G. P. Allaway | |
| A. Castillo | |||
| J. M. Orenstein | |||
| C. T. Wild | |||
| D. E. Martin | |||
| E. O. Freed | |||
| M. Reddick | |||
| K. Salzwedel | |||
| R. Goila-Gaur | |||
| N. R. Kilgore | |||
| C. Matallana | |||
| D. Zoumplis | |||
| P2860 | cites work | Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding | Q24291784 |
| Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function | Q24530772 | ||
| Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release | Q24563651 | ||
| Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag) | Q24633537 | ||
| Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production | Q27485930 | ||
| Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300 | Q28141609 | ||
| HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress | Q28207991 | ||
| Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation | Q28360742 | ||
| Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone | Q29547734 | ||
| Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene | Q29615351 | ||
| A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly | Q33782377 | ||
| The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner | Q34104639 | ||
| Time trends in primary HIV-1 drug resistance among recently infected persons | Q34136709 | ||
| p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease | Q34288376 | ||
| Viral late domains | Q34338672 | ||
| Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions | Q36624873 | ||
| Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. | Q36650046 | ||
| Maturation of dimeric viral RNA of Moloney murine leukemia virus. | Q36652049 | ||
| The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors | Q36881276 | ||
| Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes | Q39451108 | ||
| Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. | Q39579012 | ||
| Compensatory point mutations in the human immunodeficiency virus type 1 Gag region that are distal from deletion mutations in the dimerization initiation site can restore viral replication | Q39579618 | ||
| Deletion mutagenesis within the dimerization initiation site of human immunodeficiency virus type 1 results in delayed processing of the p2 peptide from precursor proteins. | Q39594983 | ||
| Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag. | Q39685850 | ||
| The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity | Q39870242 | ||
| Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli. | Q40131039 | ||
| An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. | Q41665498 | ||
| Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids | Q42285617 | ||
| Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents | Q42555749 | ||
| HIV-1 gag proteins: diverse functions in the virus life cycle | Q43783202 | ||
| Antiviral inhibition of the HIV-1 capsid protein | Q44380725 | ||
| In vitro processing of human immunodeficiency virus type 1 Gag virus-like particles | Q45741794 | ||
| Antiretroviral-drug resistance among patients recently infected with HIV. | Q46277555 | ||
| Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease | Q69564852 | ||
| Enfuvirtide | Q73411068 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| P304 | page(s) | 13555-13560 | |
| P577 | publication date | 2003-10-22 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing | |
| PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing | |||
| P478 | volume | 100 |
| Q42424208 | 3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro |
| Q28294677 | 3D Visualization of HIV Virions by Cryoelectron Tomography |
| Q44989243 | 5th Antiviral Drug Discovery and Development Summit |
| Q33326188 | A cell-penetrating helical peptide as a potential HIV-1 inhibitor |
| Q56786373 | A guided tour through the antiviral drug field |
| Q37780981 | A new functional role of HIV-1 integrase during uncoating of the viral core |
| Q33220259 | A peptide inhibitor of HIV-1 assembly in vitro |
| Q34771244 | A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsid |
| Q33560406 | A simple fluorescence based assay for quantification of human immunodeficiency virus particle release |
| Q24606079 | A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat |
| Q42546287 | A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle |
| Q37336728 | A two-pronged structural analysis of retroviral maturation indicates that core formation proceeds by a disassembly-reassembly pathway rather than a displacive transition. |
| Q40074485 | Activation and inhibition of the proteasome by betulinic acid and its derivatives |
| Q43190020 | Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity. |
| Q27324263 | Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors |
| Q46079242 | An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat |
| Q34552402 | Analysis of the N-terminal region of the murine leukemia virus nucleocapsid protein |
| Q24645221 | Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents |
| Q36275081 | Anti-AIDS agents 73: structure-activity relationship study and asymmetric synthesis of 3-O-monomethylsuccinyl-betulinic acid derivatives |
| Q33814879 | Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors |
| Q36034205 | Anti-AIDS agents 88. Anti-HIV conjugates of betulin and betulinic acid with AZT prepared via click chemistry |
| Q36340098 | Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors. |
| Q37330178 | Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents |
| Q33819240 | Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets |
| Q40262003 | Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a |
| Q40055204 | Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses |
| Q37338979 | Antiviral strategies |
| Q35889586 | Antivirals and antiviral strategies |
| Q30455050 | Assembly and architecture of HIV. |
| Q36145625 | Authentic HIV-1 integrase inhibitors |
| Q55343131 | Betulinic Acid Exerts Cytotoxic Activity Against Multidrug-Resistant Tumor Cells via Targeting Autocrine Motility Factor Receptor (AMFR). |
| Q38624961 | Betulinic Acid: Recent Advances in Chemical Modifications, Effective Delivery, and Molecular Mechanisms of a Promising Anticancer Therapy. |
| Q40063752 | Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1. |
| Q34885660 | Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection |
| Q45428884 | Blocking HIV-1 virus assembly |
| Q37448772 | Boswellic acids: a group of medicinally important compounds. |
| Q37354394 | Cancer preventive agents 9. Betulinic acid derivatives as potent cancer chemopreventive agents |
| Q28477791 | Characterization of a novel type of HIV-1 particle assembly inhibitor using a quantitative luciferase-Vpr packaging-based assay |
| Q47318968 | Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. |
| Q34468057 | Conjugates of betulin derivatives with AZT as potent anti-HIV agents |
| Q38765818 | Conserved Interaction of Lentiviral Vif Molecules with HIV-1 Gag and Differential Effects of Species-Specific Vif on Virus Production. |
| Q36950909 | Contributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly |
| Q26739673 | Coordination of Genomic RNA Packaging with Viral Assembly in HIV-1 |
| Q36673166 | Critical role of conserved hydrophobic residues within the major homology region in mature retroviral capsid assembly. |
| Q31046491 | Cyclic peptide inhibitors of HIV-1 capsid-human lysyl-tRNA synthetase interaction |
| Q39724170 | Cysteine 95 and other residues influence the regulatory effects of Histidine 69 mutations on Human Immunodeficiency Virus Type 1 protease autoprocessing |
| Q30425900 | Design of in vitro symmetric complexes and analysis by hybrid methods reveal mechanisms of HIV capsid assembly |
| Q43520047 | Design, synthesis, and anti-tumor activity of novel betulinic acid derivatives |
| Q45173552 | Determinants of activity of the HIV-1 maturation inhibitor PA-457. |
| Q34435796 | Development of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs |
| Q36523929 | Dimerization of the SP1 Region of HIV-1 Gag Induces a Helical Conformation and Association into Helical Bundles: Implications for Particle Assembly |
| Q37699332 | Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach |
| Q27321347 | Distribution and Redistribution of HIV-1 Nucleocapsid Protein in Immature, Mature, and Integrase-Inhibited Virions: a Role for Integrase in Maturation |
| Q92623235 | Dominant Negative MA-CA Fusion Protein Is Incorporated into HIV-1 Cores and Inhibits Nuclear Entry of Viral Preintegration Complexes |
| Q33801821 | Drug interactions with new and investigational antiretrovirals |
| Q28473451 | Drug-class specific impact of antivirals on the reproductive capacity of HIV |
| Q59349388 | Effect of betulinic acid and its ionic derivatives on M-MuLV replication |
| Q33614514 | Effect of dimerizing domains and basic residues on in vitro and in vivo assembly of Mason-Pfizer monkey virus and human immunodeficiency virus. |
| Q30479297 | Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells |
| Q36150601 | Emerging anti-HIV drugs |
| Q56786308 | Emerging antiviral drugs |
| Q36237524 | Emerging drug targets for antiretroviral therapy |
| Q33395056 | Enhancing the divergent activities of betulinic acid via neoglycosylation |
| Q37317698 | Eradication of HIV: current challenges and new directions |
| Q40979700 | FAITH - Fast Assembly Inhibitor Test for HIV. |
| Q28480389 | Fangchinoline inhibits human immunodeficiency virus type 1 replication by interfering with gp160 proteolytic processing |
| Q38972969 | Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions |
| Q37115695 | GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro |
| Q33990752 | Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease |
| Q33782016 | Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase |
| Q31112668 | Guanidine alkaloid analogs as inhibitors of HIV-1 Nef interactions with p53, actin, and p56lck. |
| Q27666355 | HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention |
| Q34700544 | HIV drug development: the next 25 years |
| Q34595921 | HIV entry inhibitors and their potential in HIV therapy |
| Q24614498 | HIV type 1 Gag as a target for antiviral therapy |
| Q36672006 | HIV-1 Capsid Inhibitors as Antiretroviral Agents |
| Q35761626 | HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors |
| Q37447762 | HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. |
| Q35853012 | HIV-1 antiretroviral drug therapy |
| Q38539565 | HIV-1 assembly, release and maturation. |
| Q38366763 | HIV-1 gag: an emerging target for antiretroviral therapy. |
| Q34529834 | HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice |
| Q38549717 | HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat. |
| Q37705207 | HIV-1 uncoating: connection to nuclear entry and regulation by host proteins |
| Q30980940 | Helical structure determined by NMR of the HIV-1 (345-392)Gag sequence, surrounding p2: implications for particle assembly and RNA packaging |
| Q34626162 | Highly conserved serine residue 40 in HIV-1 p6 regulates capsid processing and virus core assembly |
| Q38032330 | Human Immunodeficiency Virus Gag and protease: partners in resistance |
| Q36857103 | Human immunodeficiency virus type 1 assembly, release, and maturation. |
| Q30478394 | Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag |
| Q42361670 | Hydrogen/Deuterium Exchange Analysis of HIV-1 Capsid Assembly and Maturation |
| Q36708826 | Identification of HIV inhibitors guided by free energy perturbation calculations |
| Q34269543 | Identification of HIV-1 inhibitors targeting the nucleocapsid protein. |
| Q57459053 | Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation |
| Q35832693 | Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice. |
| Q28829072 | Identification of potent maturation inhibitors against HIV-1 clade C |
| Q37192174 | Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457) |
| Q35184863 | In vitro analysis of human immunodeficiency virus particle dissociation: gag proteolytic processing influences dissociation kinetics |
| Q30832180 | In vitro protease cleavage and computer simulations reveal the HIV-1 capsid maturation pathway |
| Q35139703 | In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). |
| Q24599377 | In vitro selection of clinically relevant bevirimat resistance mutations revealed by "deep" sequencing of serially passaged, quasispecies-containing recombinant HIV-1 |
| Q38743504 | Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1. |
| Q38716274 | Inhibition of HIV-1 Maturation via Small-Molecule Targeting of the Amino-Terminal Domain in the Viral Capsid Protein |
| Q40357793 | Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles |
| Q37676344 | Insights into the activity of maturation inhibitor PF-46396 on HIV-1 clade C |
| Q36884128 | Integrating the HIV-1 assembly/maturation pathway |
| Q38524164 | Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides. |
| Q36917141 | Irregular and Semi-Regular Polyhedral Models for Rous Sarcoma Virus Cores. |
| Q37162931 | Isolation and characterization of a small antiretroviral molecule affecting HIV-1 capsid morphology. |
| Q30372916 | MAS NMR of HIV-1 protein assemblies. |
| Q59359572 | Maturation inhibitors facilitate virus assembly and release of HIV-1 capsid P224 mutant |
| Q28554482 | Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors |
| Q34441998 | Metabolic and functional diversity of saponins, biosynthetic intermediates and semi-synthetic derivatives |
| Q64964564 | MicroED structures of HIV-1 Gag CTD-SP1 reveal binding interactions with the maturation inhibitor bevirimat. |
| Q41692107 | Molecular Events in Late Stages of HIV-1 Replication |
| Q82466284 | Molecular dynamics simulation studies of betulinic acid with human serum albumin |
| Q45421573 | Molecular factors required for human immunodeficiency virus type I infectivity |
| Q40226566 | Molecular mechanisms by which HERV-K Gag interferes with HIV-1 Gag assembly and particle infectivity |
| Q85121940 | Monolayer behavior of binary systems of betulinic acid and cardiolipin: Thermodynamic analyses of Langmuir monolayers and AFM study of Langmuir–Blodgett monolayers |
| Q37967727 | Morphogenesis of the Infectious HIV-1 Virion |
| Q64247477 | Multiple Roles of HIV-1 Capsid during the Virus Replication Cycle |
| Q34642385 | Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers |
| Q40894533 | Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. |
| Q39763774 | Mutations in the spacer peptide and adjoining sequences in Rous sarcoma virus Gag lead to tubular budding |
| Q58862085 | Natural product-derived compounds in HIV suppression, remission, and eradication strategies |
| Q36790196 | New antiretroviral agents |
| Q83142651 | New antiretroviral drugs |
| Q37901613 | New approaches for antiviral targeting of HIV assembly |
| Q35209514 | New betulinic acid derivatives as potent proteasome inhibitors |
| Q36691642 | New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1. |
| Q37450688 | New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation |
| Q43100320 | New triterpenoids from Arisaema jacquemontii |
| Q27666929 | Nine crystal structures determine the substrate envelope of the MDR HIV-1 protease |
| Q36634459 | Novel antiretroviral agents in HIV therapy |
| Q37781803 | Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results |
| Q33624690 | Novel approaches to inhibiting HIV-1 replication. |
| Q37502492 | Novel compounds for the treatment of HIV type-1 infection |
| Q42148219 | Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of ant |
| Q33957533 | Novel postentry inhibitor of human immunodeficiency virus type 1 replication screened by yeast membrane-associated two-hybrid system |
| Q37385347 | Novel targets for antiretroviral therapy: clinical progress to date |
| Q37086413 | Nucleocapsid protein function in early infection processes |
| Q93058713 | Off-Pathway Assembly: A Broad-Spectrum Mechanism of Action for Drugs That Undermine Controlled HIV-1 Viral Capsid Formation |
| Q59351133 | Pathogenic Viruses Commonly Present in the Oral Cavity and Relevant Antiviral Compounds Derived from Natural Products |
| Q26771739 | Pharmacological intervention of HIV-1 maturation |
| Q24672964 | Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection |
| Q40750425 | Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat |
| Q37143309 | Plant-derived natural product research aimed at new drug discovery |
| Q37173329 | Plant-derived triterpenoids and analogues as antitumor and anti-HIV agents |
| Q33864444 | Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat |
| Q21092230 | Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice |
| Q28469069 | Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol |
| Q33743971 | Potential role for CA-SP in nucleating retroviral capsid maturation |
| Q21284351 | Predicting Bevirimat resistance of HIV-1 from genotype |
| Q53688749 | Promiscuous, Multi-Target Lupane-Type Triterpenoids Inhibits Wild Type and Drug Resistant HIV-1 Replication Through the Interference With Several Targets. |
| Q53884808 | Promising phase I results against new HIV target. |
| Q27342743 | Protease cleavage leads to formation of mature trimer interface in HIV-1 capsid |
| Q41844750 | Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process |
| Q47107077 | Quenching protein dynamics interferes with HIV capsid maturation. |
| Q37803138 | Recent advances in anti-HIV natural products |
| Q36967857 | Recent progress in antiretrovirals--lessons from resistance |
| Q47551420 | Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives. |
| Q90646261 | Resistance to Second-Generation HIV-1 Maturation Inhibitors |
| Q38393674 | Retroviral proteases and their roles in virion maturation |
| Q24795340 | Retroviruses 2004: review of the 2004 Cold Spring Harbor Retroviruses Conference |
| Q34387732 | Revisiting HIV-1 uncoating |
| Q37772888 | Role of CXCR4 in HIV infection and its potential as a therapeutic target |
| Q33568300 | Role of protein interactions in defining HIV-1 viral capsid shape and stability: a coarse-grained analysis |
| Q34499377 | Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis |
| Q24673149 | Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers |
| Q92490664 | Second Generation Inhibitors of HIV-1 Maturation |
| Q91908886 | Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses |
| Q33769181 | Structural analysis of HIV-1 maturation using cryo-electron tomography |
| Q28485054 | Structural and functional insights into the HIV-1 maturation inhibitor binding pocket |
| Q59355393 | Structure and Anti-HIV Activity of Betulinic Acid Analogues |
| Q28828191 | Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396 |
| Q36958798 | Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation |
| Q42202820 | Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1 |
| Q42021180 | Synthesis and Biological Evaluation of Macrocyclized Betulin Derivatives as a Novel Class of Anti-HIV-1 Maturation Inhibitors |
| Q36369176 | Synthesis and biological evaluation of tricyclic guanidine analogues of batzelladine K for antimalarial, antileishmanial, antibacterial, antifungal, and anti-HIV activities |
| Q38941880 | Synthesis and cytotoxicity of triterpenoids derived from betulin and betulinic acid via click chemistry |
| Q30318499 | Synthesis, encapsulation and antitumor activity of new betulin derivatives |
| Q61445564 | Targeting HIV-1 Protease Autoprocessing for High-throughput Drug Discovery and Drug Resistance Assessment |
| Q37928913 | Targeting human immunodeficiency virus type 1 assembly, maturation and budding. |
| Q37820252 | Targeting the protein-protein interactions of the HIV lifecycle |
| Q54216802 | The Antiviral Activity of the Cellular Glycoprotein LGALS3BP/90K is Species-Specific. |
| Q36104509 | The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets |
| Q55517077 | The KT Jeang Retrovirology prize 2018: Eric Freed. |
| Q33557807 | The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates |
| Q34742382 | The TY3 Gag3 spacer controls intracellular condensation and uncoating |
| Q33727091 | The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation |
| Q27009643 | The choreography of HIV-1 proteolytic processing and virion assembly |
| Q36544929 | The clinical pharmacology of antiretrovirals in development |
| Q37492757 | The conserved carboxy terminus of the capsid domain of human immunodeficiency virus type 1 gag protein is important for virion assembly and release |
| Q28259321 | The design of drugs for HIV and HCV |
| Q36187060 | The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV. |
| Q30440445 | The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain |
| Q42934339 | The ins and outs of viral infection: keystone meeting review |
| Q21245046 | The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles |
| Q24793247 | The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid |
| Q30437103 | The structural biology of HIV assembly |
| Q36656440 | The structural biology of HIV-1: mechanistic and therapeutic insights |
| Q44525735 | Three-dimensional structure of HIV-1 virus-like particles by electron cryotomography. |
| Q39630669 | Triterpene derivatives that inhibit human immunodeficiency virus type 1 replication |
| Q43924337 | Triterpenoids from Ocimum labiatum Activates Latent HIV-1 Expression In Vitro: Potential for Use in Adjuvant Therapy. |
| Q33356201 | Understanding HIV-1 protease autoprocessing for novel therapeutic development |
| Q58388992 | Update on the development of HIV entry inhibitors |
| Q33774977 | Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid |
| Q24642446 | Virus maturation as a new HIV-1 therapeutic target |
Search more.